Details

Autor(en) / Beteiligte

• Albrecht, Thomas
• Waliszewski, Matthias
• Roca, Catherine
• Redlich, Ulf
• Tautenhahn, Jörg
• Pech, Maciej
• Halloul, Zuhir
• Gögebakan, Özlem
• Meyer, Dirk-Roelfs
• Gemeinhardt, Ines
• Zeller, Thomas
• Müller-Hülsbeck, Stefan
• Ott, Ilka
• Tepe, Gunnar

Titel

Two-Year Clinical Outcomes of the CONSEQUENT Trial: Can Femoropopliteal Lesions be Treated with Sustainable Clinical Results that are Economically Sound?

Ist Teil von

• Cardiovascular and interventional radiology, 2018-07, Vol.41 (7), p.1008-1014

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2018

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• Purpose The previously reported 6-month angiographic and 12-month clinical outcomes of the CONSEQUENT trial demonstrated the safety and efficacy of a novel paclitaxel–resveratrol-coated balloon for the treatment of lesions in the femoropopliteal segment. The purpose of this report is to present the 2-year results including a cost-benefit analysis for Germany. Materials and Methods Patients with symptomatic peripheral artery occlusive disease in femoropopliteal lesions were randomized either to drug-coated balloon (DCB, n  = 78) or plain old balloon angioplasty (POBA, n  = 75). As secondary endpoints, the 2-year clinical results consisting of target lesion revascularization (TLR), patency and increase in walking distance were recorded. Based on the Kaplan–Meier analyses for TLR and other adverse events, a cost-benefit analysis was conducted for the German DRG system. Results There were no additional TLRs in both groups between 14 and 24 months so that the corresponding rates remained significantly different between the treatment groups (DCB: 19.1 vs. POBA 40.6%, p  = 0.007). At 2 years, the patency rate was significantly higher in the DCB group (72.3 vs. 48.4%, p  = 0.006). The walking distance increase was also significantly higher after DCB angioplasty (172 ± 103 vs. 52 ± 136 m, p  = 0.001). We estimated 2-year cost savings of € 1111.97 per patient treated with DCB instead of POBA. Conclusions The use of paclitaxel–resveratrol matrix-coated peripheral balloons compared to POBA was associated with a significantly reduced TLR rate, superior patency and substantial cost savings at 2 years. ClinicalTrials.gov Identifier NCT01970579.